https://orcid.org/0000-0002-8265-5400
References
- Nair T, Fitzgerald J, Ly B, et al. Dalbavancin as a cost effective antibiotic. Infect Dis. 2018;50(1):75–76.
- Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304–307.
- Marcellusi A, Bini C, Andreoni M, et al. Budget impact analysis of dalbavancin in the treatment of acute bacterial skin and skin structure infections in three European countries. Clin Drug Investig. 2020;40(4):305–318.
- Arrieta-Loitegui M, Caro-Teller JM, Ortiz-Pérez S, et al. Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm. 2020. DOI:10.1136/ejhpharm-2020-002315
- Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;6(1):ofy331.
- Almangour TA, Perry GK, Alhifany AA. Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study. Saudi Pharm J. 2020;28(4):460–464.
- De Vito A, Geremia N, Fiore V, et al. Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy. Eur Rev Med Pharmacol Sci. 2020;24(14):7861–7868.